Dr. Gregory Stock

[sws_ui_tabs ui_theme=”ui-smoothness” size=”665″][tabs_panel title=”Bio”]

1Questions are Gregory Stock’s passion. He started asking them as a child and never stopped. His question books—including The Kids’ Book of Questions and Love & Sex: The Book of Questions—are miniclassics that have sold more than 4 million copies and have been translated into 18 languages.

[sws_blue_box box_size=”640″ align=”left”]To visit Dr. Stock’s web site please go to www.gregorystock.net. Please note: This website is Flash intensive, and will require a browser that supports Adobe Flash [/sws_blue_box]

Dr. Stock is also a biotech entrepreneur, bioethicist, science author, public communicator, and a leading authority on the broad impacts of genomic and other advanced technologies in the life sciences. He has a PhD from Johns Hopkins and an MBA from Harvard. He serves on the California Advisory Committee on Stem Cells and Cloning and on the editorial boards of the Journal of Evolution & Technology and Rejuvenation Research. He has written more than 60 science and policy papers and 3 influential books on technology, ethics, and public policy in the life sciences: Engineering the Human Germline; Metaman: The Merging of Humans and Machines into a Global Superorganism; and Redesigning Humans: Our Inevitable Genetic Future, which won the Kistler Book Prize for science books.

Stock has made more than 1,000 media appearances to discuss questions and values, and he frequently appears on TV and radio as an authority on the implications of genomics and other technologies,. He was the founding director of Program on Medicine, Technology & Society at the UCLA School of Medicine, the founding CEO of both Signum Biosciences, which is developing therapeutics for Alzheimer’s, and Ecoeos, which will be launching a genetic test to gauge personal sensitivity to mercury exposure, and serves on various boards.

[/tabs_panel] [tabs_panel title=”Bio-Extended”]

1Dr. Gregory Stock, a biotech entrepreneur, bioethicist, best-selling author and public communicator is a leading authority on the broad impacts of genomic and other advanced technologies in the life sciences. He founded the influential Program on Medicine, Technology and Society at UCLA’s School of Medicine in 1997 and served as its director for ten years while leading a broad effort to explore critical technologies poised to impact humanity’s future and reshape medical science. Through a series of high-profile symposia, lectures, and media appearances, Stock has catalyzed broad public debate about the social and public policy implications of today’s revolution in molecular genetics and bioinformatics, and about how most effectively to translate progress in basic science into improved therapeutics and healthcare.

[sws_blue_box box_size=”640″ align=”left”]To visit Dr. Stock’s web site please go to www.gregorystock.net. Please note: This website is Flash intensive, and will require a browser that supports Adobe Flash [/sws_blue_box]

Dr. Stock is a strong advocate for aggressive biomedical funding and research, and for cautious governmental oversight. In 2004, Stock co-founded Signum Biosciences , a Princeton University spinoff created to develop a new class of anti-inflammatories and therapeutics for neurodegeneration. He served as the CEO of Signum for 6 years directing efforts there to develop promising pharma candidates for Alzheimer’s and Parkinson’s. In 2010, he co-founded Ecoeos, a consumer-products personalized-healthcare company that has developed a genetic test for individual susceptibility to mercury toxicity. He served as CEO of Ecoeos for the past two years.

Dr. Stock has been an invited speaker to many academic, government and business conferences. He sits on the editorial board of the American Journal of Bioethics, The Journal of Evolution and Technology, and Rejuvenation Research and was invited to submit an Advisory Memo to the President on the challenges ahead. Stock has been profiled in the Wall Street Journal, New York Times, MIT Tech Review and Lancet. He makes regular appearances on television and radio, including CNN, PBS, NPR, Bloomberg and the BBC and frequently debates biotech policy with Francis Fukuyama, Jeremy Rifkin, Leon Kass, Daniel Callahan, Bill McKibben, George Annas and other prominent voices who would rein in biomedical research.

Dr. Stock’s book, Redesigning Humans: Our Inevitable Genetic Future with Houghton Mifflin won the prestigious Kistler Book Prize for Science books and was nominated for a Wired Rave Award. Among his other books are Engineering The Human Germline: An Exploration of the Science and Ethics of Altering the Genes We Pass to Our Children with Oxford University Press, Metaman: The Merging of Humans and Machine into a Global Superorganism with Simon & Schuster, and the best selling, Book of Questions with Workman Press, which has sold over 2.5  million copies and been translated into 19 languages. It was in its sixty-eighth printing in September 2013, when it was replaced by a new edition, completely updated and revised to reflect among other things the new possibilities and dilemmas attending our recent rapid advances in life sciences and communications. Sequels to the original Book of Questions include The Book of Questions: Business, Politics, and Ethics, The Book of Questions: Love and Sex, and The Kids’ Book of Questions.

Gregory Stock serves on the California Advisory Committee on Stem Cells and Reproductive Cloning and is the Associate Director of the Center for Life Science Policy Studies, a policy think tank at the University of California at Berkeley. He serves on the boards of Signum Biosciences, Ecoeos, and Napo Pharmaceuticals, a private pharmaceutical company with an important drug that was recently approved for diarrhea associated with HIV retroviral therapy. He has a Doctorate in Biophysics from Johns Hopkins University and an MBA from Harvard University.[/tabs_panel] [/sws_ui_tabs]